Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

The content on this page is being archived for historic and reference purposes only. The content, links, and pdfs are no longer maintained and might be outdated.

Unusual Syndrome with Fatalities among Premature Infants: Association with a New Intravenous Vitamin E Product

Since March 9, 1984, CDC has received reports from two hospitals of clusters of an unusual illness occurring among low-birthweight (less than 1,500 grams), premature infants in neonatal intensive-care units. Thirteen affected infants in these two hospitals developed clinically significant ascites, in addition to some or all of the following abnormalities: hepatomegaly, splenomegaly, cholestatic jaundice, azotemia, and thrombocytopenia. Eight infants have died. All affected infants had received parenteral nutrition therapy, in addition to other supportive measures and therapeutic interventions common to the care of low-birthweight infants. An intravenous vitamin E preparation, containing 25 mg/ml vitamin E, 9% polysorbate 80 and 1% polysorbate 20 in 2-ml vials (E-Ferol Aqueous SolutionR, distributed by O'Neal, Jones & Feldman, St. Louis, Missouri), was introduced in each hospital for addition to parenteral nutrition solutions approximately 1 month before the onset of illness in the first infant in both clusters. All affected infants received E-Ferol; some affected infants received up to 1 ml or more daily. Both outbreaks ceased shortly after use of E-Ferol was discontinued.

In collaboration with the state health departments, CDC is conducting ongoing epidemiologic investigations at both institutions. Although the etiology and pathophysiology of this syndrome are presently unclear, the U.S. Food and Drug Administration (FDA) and CDC recommend that E-Ferol not be used. FDA and the distributor have initiated a voluntary recall of the product. The product, which has been marketed since December 1983, is not the subject of an Approved New Drug Application by FDA. Reported by V Lorch, MD, MD Murphy, MD, University of Tennessee Research Center and Hospital, Knoxville, RH Hutcheson, MD, State Epidemiologist, Tennessee Dept of Health and Environment; N Kosmetatos, MD, D Frank, MD, Good Samaritan Hospital, Cincinnati, TJ Halpin, MD, State Epidemiologist, Ohio State Dept of Health; Center for Drugs and Biologics, US Food and Drug Administration; Hospital Infections Program, Div of Viral Diseases, Center for Infectious Diseases, Center for Environmental Health, CDC.

Editorial Note

Editorial Note: Premature neonates are reported to have a relative deficiency of vitamin E at birth, which has been associated with hemolytic anemia in premature infants (1). Although vitamin E is reported to have a therapeutic benefit in treating this form of hemolytic disease in premature infants and may have a role in preventing the development of retrolental fibroplasia and bronchopulmonary dysplasia in infants requiring oxygen therapy, the benefit, risk, and dosage relationships are, at present, uncertain (1,2).

Other vitamin E preparations are available for enteral, subcutaneous, and intramuscular administration. Vitamin E is a component, at lower concentrations, of multivitamin preparations for intravenous use. Use of these alternative vitamin E preparations has not been temporally associated with the severe clinical syndrome described above. However, other complications, such as cholestatic jaundice, have been associated with total parenteral nutrition therapy (3), and thrombocytopenia with lipid emulsion therapy (4).

Additional reports of similar severe illness should be reported through appropriate state health officials to the Epidemiology Development Branch, Division of Drug and Biologic Experience, FDA (301) 443-6410 or the Hospital Infections Program, Center for Infectious Diseases, CDC (404) 329-3406.

References

  1. Ehrenkranz RA. Vitamin E and the neonate. Am J Dis Child 1980;134:1157-66.

  2. Hittner HM, Godio LB, Rudolph AJ, et al. Retrolental fibroplasia: efficacy of vitamin E in a double blind clinical study of preterm infants. N Eng J Med 1981;305:1365-71.

  3. Bernstein J, Chang CH, Brough AJ, Heidelberger KP. Conjugated hyperbilirubinemia in infancy associated with parenteral alimentation. J Pediatr 1977;90;361-7.

  4. Lipson AH, Pritchard J, Thomas G. Thrombocytopenia after intralipid infusion in a neonate. Lancet 1974;I:1462-3.

Disclaimer   All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Page converted: 08/05/98

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services

This page last reviewed 5/2/01